☰

Pancreatic Cancer Clinical Trials

Last reviewed: November 17, 2026

Start with the pathology report, whether surgery is possible, exact prior treatments and your molecular results. First-line, maintenance, post-progression and after-surgery studies have different requirements.

Answer a few questions to find clinical trials matched to your specific Pancreatic Cancer situation.

A thorough search takes ~15 minutes — we'll email your results. No sign-up.

Find matching trials →
🎉 FDA APPROVAL (August 26, 2026): The FDA approved daraxonrasib (RASONQUE) for adults with metastatic pancreatic adenocarcinoma who have had ≥1 prior systemic therapy or are not candidates for multiagent chemotherapy — the first RAS-targeted therapy ever approved for pancreatic cancer. Basis: the pivotal Phase 3 RASolute 302 (NCT06625320, previously-treated metastatic PDAC, n=500), which showed median overall survival 13.2 vs 6.7 months (HR 0.40, p<0.0001) — a 60% reduction in the risk of death, PFS 7.2 vs 3.6 months, ORR 30% vs 11%. Recommended dose 300 mg orally once daily. These group results do not predict an individual outcome. The recruiting Revolution Medicines RAS(ON) PDAC trials (below) test daraxonrasib in earlier settings — 1L metastatic and adjuvant.
🔔 Post-ASCO 2026 (May 29 – June 2) update: KRAS-directed studies are an important part of pancreatic cancer research. Three new KRAS G12D Phase 3 trials launched in July 2026: NCT07621718 zoldonrasib (RMC-9805) + chemo 1L metastatic, NCT07522073 INCB161734 + chemo 1L KRAS G12D, and NCT07409272 setidegrasib (ASP3082) KRAS G12D degrader + mFOLFIRINOX/NALIRIFOX. The daraxonrasib (RMC-6236, pan-RAS(ON)) Phase 3 PDAC program — RASolute 303 NCT07491445 (1L metastatic) and RASolute 304 NCT07252232 (resected adjuvant) — is being studied in earlier treatment settings. Two more new entrants: NCT07562152 atebimetinib + GnP (MEK), NCT07490301 telisotuzumab adizutecan + FOLFOX (c-MET ADC). Cross-link: KRAS Inhibitors hub for the cross-cancer view; CLDN18.2 hub for the CLDN18.2 ADC + CAR-T landscape.

Current Clinical Trial Landscape

Active research areas in 2026:

Standard of care: For resectable disease: surgery followed by adjuvant modified FOLFIRINOX (6 months) or gemcitabine + capecitabine. Neoadjuvant chemotherapy increasingly used for borderline resectable. For locally advanced: FOLFIRINOX or gemcitabine/nab-paclitaxel, with radiation in selected cases. For metastatic: NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/leucovorin; FDA first-line approval Feb 2024), FOLFIRINOX (fit patients) or gemcitabine/nab-paclitaxel. For the rare NRG1 fusion-positive tumors, zenocutuzumab (Bizengri) after prior therapy (accelerated approval Dec 2024). Olaparib maintenance for germline BRCA1/2-mutated metastatic disease without progression after at least 16 weeks of first-line platinum treatment (POLO); PALB2 alone does not establish this approved indication. Second-line: daraxonrasib (FDA Aug 26, 2026, RASolute 302; after ≥1 prior systemic therapy) or nanoliposomal irinotecan + 5-FU/leucovorin (NAPOLI-1).

Key Biomarkers for Trial Eligibility

Ask the treating team about germline testing and tumor molecular profiling; a molecular finding alone does not establish treatment or trial eligibility:

Know your KRAS variant and BRCA status? Get matched to pancreatic cancer trials in minutes.

Find Matching Trials

Selected Trials by Treatment Setting

First-Line Metastatic

FOLFIRINOX or gemcitabine/nab-paclitaxel remain standard. Trials add novel agents:

Additional selected recruiting studies

First-line maintenance research

Maintenance is a strategy after initial treatment control, not treatment after progression.

Second-Line / Pretreated

Resectable / Borderline Resectable / Locally Advanced

KRAS-Targeted Therapies

Over 90% of pancreatic cancers have KRAS mutations. Once considered undruggable, KRAS is being tested in several Phase 3 PDAC studies: daraxonrasib (RMC-6236, pan-RAS(ON)) in both 1L metastatic and adjuvant-resected Phase 3; zoldonrasib (RMC-9805) and INCB161734 KRAS G12D RAS(ON) Phase 3; setidegrasib (ASP3082) KRAS G12D degrader Phase 3; HRS-4642 G12D for borderline resectable; HLA-matched KRAS G12V TCR-T (NCT04146298). For the cross-cancer KRAS class (sotorasib + adagrasib + calderasib + olomorasib + glecirasib + garsorasib in NSCLC + CRC), see the KRAS Inhibitors hub.

KRAS G12R and G12V Pancreatic Cancer: Which Trials Accept Your Variant

Most new KRAS drugs in pancreatic cancer target G12D. If your tumor carries KRAS G12R or KRAS G12V, check each trial's list of allowed mutations: the newer "pan-KRAS" inhibitors do not all cover every variant. The trials below were checked against their published registry criteria on November 17, 2026. The trial team must confirm eligibility and cohort availability.

KRAS G12R (~15% of PDAC)

G12R is common in pancreatic cancer but rare elsewhere, so few trials are built for it. Two pan-KRAS inhibitor trials list their allowed mutations without G12R: BBO-11818 (NCT06917079) and BLU-924 / SAR449336 (NCT07629960). Studies whose published molecular criteria can include G12R; other entry criteria and cohort availability still apply:

KRAS G12V (~30% of PDAC)

For the full cross-cancer picture, see the KRAS Inhibitors hub.

Novel Approaches

A November 17 registry search for pancreatic cancer, recruiting interventional studies returned 667 records, including 59 with a Phase 3 component. This broad query includes supportive care, imaging, basket trials and other pancreatic tumor types; it is not a count of PDAC treatment options. Selected studies; overall recruitment is not proof of a local enrollment slot. Three cited studies are active, not recruiting (NCT03257033, NCT05482516 and historical RASolute 302 NCT06625320); HRS-2329 NCT07736612 is not yet recruiting. Status checked November 17, 2026. Search current recruiting interventional trials on ClinicalTrials.gov.

Primary sources: FDA daraxonrasib indication and trial results; NCI pancreatic treatment PDQ; FDA tumor-agnostic T-DXd indication. Each study link opens its registry record.

Frequently Asked Questions

How do I find pancreatic cancer clinical trials I'm eligible for?

Enter your pancreatic cancer details into ClinTrialFinder — including KRAS mutation type (G12D, G12V, G12C, G12R), BRCA/PALB2 status, disease stage (resectable, borderline, locally advanced, metastatic), and prior treatments. The AI matches you with trials based on your specific profile in minutes. No login required.

What pancreatic cancer trials are currently recruiting?

Research includes RAS/KRAS inhibitors, CLDN18.2-directed treatments, chemotherapy combinations, cell therapies and maintenance studies. Check the dated selected-study listings and current registry search; first-line, post-progression, maintenance and after-surgery cohorts are different. Overall recruiting status does not guarantee a slot at your preferred hospital.

Should I get molecular profiling for pancreatic cancer?

Discuss germline testing and tumor molecular profiling with your treating team. KRAS variant, BRCA1/2 or PALB2, MSI/MMR, NTRK and HER2 testing may guide options. Approved pancreatic olaparib maintenance requires germline BRCA1/2-mutated metastatic disease without progression after at least 16 weeks of first-line platinum. PALB2 alone does not establish that indication; tumor-agnostic T-DXd requires HER2 IHC 3+ plus other clinical criteria.

Are KRAS-mutant pancreatic cancers now treatable with targeted therapy?

In the US, daraxonrasib is approved for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or when multiagent systemic therapy is unsuitable. Earlier-stage and first-line combinations remain distinct research settings. KRAS G12D/G12V-selective agents, vaccines and TCR-T therapies have protocol-specific molecular, HLA and prior-treatment criteria.

Are there clinical trials for KRAS G12R pancreatic cancer?

Yes, but fewer than for G12D. Daraxonrasib (RASONQUE), a pan-RAS(ON) inhibitor that covers G12R, was FDA-approved in August 2026 for metastatic pancreatic cancer after at least one prior therapy. Trials that accept G12R include daraxonrasib's RASolute 303 (first-line, NCT07491445) and RASolute 304 (after surgery, NCT07252232), ASP5834 (NCT07094204), PT0511 (NCT07300150), and the ELI-002 7P KRAS vaccine for resectable disease (NCT07671339). Some pan-KRAS inhibitor trials, such as BBO-11818 and BLU-924, do not list G12R, so check each trial's allowed mutations.

What clinical trials are there for KRAS G12V pancreatic cancer?

Potential studies include RMC-5127, selected pan-KRAS/pan-RAS trials and HLA-matched TCR-T therapies. G12V alone does not establish eligibility. JAB-23E73 combination study NCT07640295 is Phase 1/2, first-line metastatic PDAC and excludes prior KRAS/RAS inhibitors. TCR study NCT04146298 requires HLA-A*11:01 and specified prior treatment.

Find Pancreatic Cancer Trials Matched to Your Situation

Enter your KRAS mutation type, BRCA status, and disease stage to get AI-matched trial results in minutes.

Find Matching Trials